MRI contrast developer Advanced Magnetics said it issued 1.2 million shares of common stock, raising $31.7 million after deducting fees and expenses.
The proceeds from the transaction will be used to fund clinical development programs, including continued development of the company's ferumoxytol as an iron replacement therapeutic, and for general working capital purposes, the company said.
By AuntMinnie.com staff writers
March 8, 2006
Related Reading
Advanced Magnetics to defend Cytogen suit, January 30, 2006
Cytogen sues Advanced Magnetics, January 26, 2006
FDA requests Combidex information, March 24, 2005
U.S. panel rejects Advanced Magnetics imaging agent, March 4, 2005
Combidex gets FDA review date, February 1, 2005
Copyright © 2006 AuntMinnie.com
